Radionuklidbehandling af neuroendokrine tumorer

Jann Mortensen, Peter Oturai, Liselotte Højgaard, Ulrich Knigge, Carsten Palnæs Hansen, Lars Martiny, Palle Rasmussen, Andreas Kjær

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with 177 Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
    Original languageDanish
    JournalUgeskrift for Laeger
    Volume172
    Issue number43
    Pages (from-to)2950-2953
    ISSN0041-5782
    Publication statusPublished - 2010

    Keywords

    • Hevesy laboratory
    • Radiation research and nuclear technologies

    Cite this

    Mortensen, J., Oturai, P., Højgaard, L., Knigge, U., Palnæs Hansen, C., Martiny, L., Rasmussen, P., & Kjær, A. (2010). Radionuklidbehandling af neuroendokrine tumorer. Ugeskrift for Laeger, 172(43), 2950-2953.